San Diego-based biopharmaceutical company, Fate Therapeutics, Inc., is currently in the clinical stages of developing programmed cellular immunotherapies designed to treat cancer and immune disorders worldwide. A notable subset of the company's product candidates, which include chimeric antigen receptor (CAR)-targeted NK and T-cell contenders FT576 and FT522, target multiple myeloma and lymphoma or autoimmune disorders, respectively. Fate Therapeutics is also spearheading CAR T-cell programs, featuring FT819 to treat hematologic malignancies and solid tumors and FT825 to treat solid tumors. In efforts to expand its offerings, the company entered into a pivotal collaboration and option agreement with Ono Pharmaceutical Co. Ltd. to develop and commercialize off-the-shelf iPSC-derived CAR T-cell product candidates with the goal of cancer treatment. Fate Therapeutics was founded in 2007.
Fate Therapeutics's ticker is FATE
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Fate Therapeutics
It is fatetherapeutics.com
Fate Therapeutics is in the Healthcare sector
Fate Therapeutics is in the Biotechnology industry
The following five companies are Fate Therapeutics's industry peers: